AUSTRALIA AU Price (at 10:49, 11 Apr 2013 GMT) Outperform A$59.35 Volatility index Low 12-month target A$ 63.85 12-month TSR % +9.6 Valuation A$ 59.84 - DCF (WACC 8.5%, beta 0.9, ERP 5.0%, RFR 5.0%, TGR 2.5%) GICS sector Pharmaceuticals, Biotechnology & Life Sciences Market cap A$m 29,390 30-day avg turnover A$m 76.1 Number shares on issue m 495.2 Investment fundamentals Year end 30 Jun 2012A 2013E 2014E 2015E Revenue m 4,616.4 5,015.3 5,455.7 5,975.3 EBIT m 1,267.9 1,587.7 1,795.3 2,018.7 Reported profit m 1,024.1 1,267.7 1,435.2 1,632.9 Adjusted profit m 1,024.1 1,267.7 1,435.2 1,632.9 Gross cashflow m 1,202.1 1,468.0 1,656.0 1,879.4 CFPS 230.9 293.4 340.0 386.9 CFPS growth % 15.2 27.0 15.9 13.8 PGCFPS x 27.1 21.3 18.4 16.2 PGCFPS rel x 2.85 2.19 2.15 2.06 EPS adj 196.7 253.3 294.7 336.1 EPS adj growth % 16.3 28.8 16.3 14.1 PER adj x 31.8 24.7 21.2 18.6 PER rel x 2.05 1.59 1.52 1.44 Total DPS 86.5 105.0 125.0 145.0 Total div yield % 1.4 1.7 2.0 2.3 Franking % 0 0 0 0 ROA % 22.3 26.8 28.2 27.5 ROE % 27.7 36.1 37.7 35.8 EV/EBITDA x 22.2 17.4 15.3 13.6 Net debt/equity % 3.4 12.2 5.9-7.4 P/BV x 9.1 8.7 7.5 6.0 AU vs ASX 100, & rec history Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, April 2013 (all figures in USD unless noted) : Global plasma report Structural advantage Event We examine global industry growth for CY12 and the relative performance of fractionators, and also discuss the sustainability of s outperformance. Impact Industry growth a very healthy 9.1%, again growing the fastest: Plasma revenues excluding recombinants grew by 9.1% in USD terms in CY12, ahead of last year s 7.3%. At a company level again outperformed with 11.3% cc growth outstripping all competitors except which was returning from a product recall. Over the past 2y has now averaged 11.6% cc top-line growth, materially higher than its two largest competitors, (7.1%) and (5.5%). Cost advantage a key driver of strong top-line growth: Because margins for the incremental unit of production are much lower than the first unit, expansion within the plasma industry generally carries margin pressure. The extent of pressure however is highly dependent on the cost base of a company, meaning that efficient manufacturers can grow their top-line faster than less-efficient manufacturers for the same level of margin pressure. Consistent with this, over the past 5 years has grown revenues faster than its competitors (12.8% pa) as well as expanded margins more (+4.9%). Structural advantage is self reinforcing, bodes well for future growth: As greater scale brings with it greater efficiencies, we believe s margin advantage will likely widen, and with it its ability to capture a greater share of growth than its competitors. We re therefore confident the company can maintain revenue growth in excess of the industry for some time yet something the equity market appears to doubt with consensus expecting growth to revert to 7.6% after next year. High China albumin share and sub-q exposure also boosting growth: Also boosting s top-line is its high share in the China albumin market which continues to grow in excess of 20%. This obviously helps albumin growth but more importantly underpins Ig growth for the company outside of China, due to the interdependency between the two products. Earnings and target price revision No change Price catalyst 12-month price target: A$63.85 based on a DCF methodology. 11 April 2013 Macquarie Securities (Australia) Limited Catalyst: Results of BAX-sponsored P3 Ig Alzheimer s trial May-June Action and recommendation Maintain Outperform: Accelerating market growth makes us increasingly positive on our 12 month industry outlook. We are also buoyed by s continuing outperformance, a trend we see continuing given the structural cost advantage we believe it has. Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com/disclosures.
: Global plasma report Global market growing at 9.1%, continuing to take share We have updated our global plasma market model which tracks revenues for 86% of the global commercial plasma fractionation industry. Fig 1 Market growth has accelerated to 9.1% Revenues (US$m) 12,000 10,000 8,000 20% 14% 3.1% 9.1% 07-12 CAGR 7.3% 13.7 % 5.4 % 11.2 % 9.7 % 12.8 % 10.6 % 6,000 4,000 2,000 0 CY07 CY08 CY09 CY10 CY11 CY12 Note: Excludes recombinants & vaccines. Top 6 fractionators represent 86% of plasma market (excluding not-for-profit). s figures represent Behring and Albumin sales into China. figures exclude raw plasma sales in CY11. All figures in USD. Source: Company reports, Macquarie Research, April 2013 Ig and Albumin again the drivers of growth: Consistent themes from the company result commentary were (i) that demand and growth of Ig remains robust, and (ii) that albumin sales have accelerated, particularly into China. We have also noticed less frequent references to pricing pressure in Europe with a number of fractionators commenting about stabilisation of prices towards the end of the year. Industry continues to recover from a tough CY10: 2010 was an unexpectedly flat year (by this industry s standards), something we attribute to (i) Government austerity measures (especially Germany & Spain), and (ii) de-stocking post the Octagam recall in September impacted industry growth in 2010. With 2012 being the second consecutive year of high single-digit revenue growth, we are further reassured that events in 2010 were one-off in nature. continues to grow faster than market: As shown in figure 1 above, has grown faster than all other fractionators in the past 5 years except emerging fractionator. This trend remained in place in 2012, with only (who was returning from a product recall) posting higher growth: Fig 2 is growing considerably faster than peers 7.7% 6.4% 11.3% 12.0% Revenue growth (cc) CY12 CY11 6.0% 5.0% -9.0% 40.1% 2.3% 4.3% Note: and do not provide cc commentary so EUR figures used instead. represents Behring sales incl China. BAX represents BioScience sales. Source: Company statements, Macquarie Research April 2013 11 April 2013 2
: Global plasma report to continue to grow faster than market has an efficiency advantage over its competitors: As depicted below, has a considerably higher EBITDA margin than most of its competitors. We have however excluded from our analysis as its margins are distorted by its large hospital consumables business. Fig 3 has a material cost advantage over its competitors CY12 EBITDA Margin¹ 31.9% 35.6% Kedrion 24.1% 14.9% 17.3% LFB -1.7% 1. All figures are for Group EBITDA margin. LFB and Kedrion are for CY11, as CY12 numbers are yet to be published. figure is for FY1H13. Source: Company reports, Macquarie Research, April 2013 Industry has inherent margin pressure: Because (i) fractionators only sell two products (Ig and albumin) in the incremental litre of raw plasma processed each year, (ii) these products generally grow faster than the other products, and (iii) COGS follows Ig and albumin growth (ie the fastest growing products), expansion in the plasma industry is generally associated with margin pressure 1. However, the extent of the pressure is dependent on the efficiency of a manufacturer: An inefficient manufacturer with an incremental cost of production of $280/L will make EBITDA of ~$20 2 for every expansionary unit at an incremental margin of 6%. Conversely an efficient manufacturer with an incremental cost of $220/L, will reap $80 EBITDA at an incremental margin of 27%. Hence efficient manufacturers can expand at a faster rate than less-efficient manufacturers for the same amount of margin pressure, and will tend to capture a disproportionate share of industry growth. Fig 4 s cost advantage allows it to grow faster and incur less margin pressure 5y average Revenue growth¹ Change in Margin 2008-12² 13.7% 4.9% 12.8% 2.9% 11.2% LFB -3.2% Kedrion 11.2% -4.3% 9.7% Kedrion -4.5% 5.4% -14.0% 1. All figures are in USD. Kedrion numbers are up until CY11, as CY12 numbers are yet to be published. 2. Figure represents absolute change in Group EBITDA margin. LFB figure is for 2011 vs 2010 and Kedrion is 2011 vs 2008 due to lack of available data. Source: Company reports, Macquarie Research, April 2013 1 In other words, if a fractionator wishes to grow Ig and Albumin (which account for ~50-60% of revenue) at the same rate as market growth, and these products continue to grow faster than infra-marginal products, they will experience margin pressure. We estimate Ig and albumin are currently growing at 2-4% faster than infra-marginal products 2 Assumes Ig yield of 4g/L & price of $60, and albumin yield of 25g/L and price of $2.50/g. 11 April 2013 3
: Global plasma report Structural advantage is self reinforcing, bodes well for future growth: As greater scale brings with it greater efficiencies, we believe s margin advantage will likely widen, and with it its ability to capture a greater share of growth than its competitors. This will then further expand its efficiency advantage, and so on and so forth. As such we are therefore confident the company can maintain revenue growth in excess of the industry for some time yet something the market appears to doubt with consensus sales growth (Bloomberg) decreasing to 7.6% after next year. China exposure and sub-q will also continue to boost growth has the highest exposure to fast-growing China albumin market: China is now the largest consumer of albumin globally with a market more than twice the size of the US, and continues to grow rapidly., largely due to entering the Chinese market before its competitors, has the largest share of the international fractionators something we don t see changing given the difficulties in distributing the product in China. This obviously bodes well for s albumin sales growth, but more importantly it underpins Ig growth (which accounts for ~3x more revenues than albumin) outside of China, due to the inter-dependency of production of the two products 3. Fig 5 has highest share in fast-growing China albumin market Albumin Market Size ($USm) $1,170 Albumin Market Growth 20% 22% China Albumin Market Share $424 57% 17% 10% 9% 8% Domestic USA China 2003-11 CAGR Source: MRB, China Biologics annual accounts, CMS pricing schedule, Macquarie Research, April 2013 CY11 has highest exposure to fast growing sub-q segment: Sub-Q Ig, which is administered under the skin at home, is a fast growing segment of the Ig market, particularly in the US, where we estimate it accounts for ~10% of the market and is growing at 20-25% pa. currently has the only high-concentration product (Hizentra), which allows users to infuse less-frequently and hence has a very high share in this fast growing market. is developing a competing high dose product, however as it has had some setbacks in the regulatory process, we see continuing to dominate this segment, at least for the remainder of this year. 3 Albumin and Ig are the only last-litre products so fractionators will only generally increase plasma production if they believe they can sell both products. 11 April 2013 4
: Global plasma report Fig 6 ( AU) 30 Jun 1H/11A 2H/11A 1H/12A 2H/12A 1H/13A 2H/13E 2011A 2012A 2013E 2014E Valuation NPV $ 59.84 Price Target $ 63.85 Profit & Loss 1H/11A 2H/11A 1H/12A 2H/12A 1H/13A 2H/13E 2011A 2012A 2013E 2014E Sales Behring $USm 1611.0 1766.0 1883.2 1879.8 1964.3 2065.0 3377.0 3763.1 4029.3 4407.3 Other Human Health $USm 360.5 360.5 440.8 412.5 518.0 468.0 721.0 853.3 986.0 1048.4 Sales Revenue $USm 1971.5 2126.5 2324.0 2292.3 2482.3 2533.0 4098.0 4616.4 5015.3 5455.7 - growth % 0.3% 9.4% 17.9% 7.8% 6.8% 10.5% 12.6% 8.6% 8.8% Interest Income $USm 18.6 8.8 14.9 27.9 17.1 16.4 27.5 42.8 33.5 41.4 Intellectual Property/Licensing $USm 46.5 46.5 82.0 60.3 71.9 71.3 93.0 142.3 143.2 142.5 Other $USm 154.3-51.2 8.1 4.1 12.4 0.0 103.1 12.1 12.4 0.0 + Other Revenue $USm 219.4 4.1 105.0 92.3 101.4 87.7 223.5 197.2 189.1 183.9 Total Revenue $USm 2191.0 2130.6 2429.0 2384.6 2583.7 2620.7 4321.6 4813.6 5204.4 5639.6 Revenue growth 6.1% 7.0% 10.9% 11.9% 6.4% 9.9% 6.5% 11.4% 8.1% 8.4% EBITDA Behring $USm 651.6 601.4 646.7 712.2 860.2 845.3 1253.0 1358.9 1705.5 1799.9 Other Human Health $USm 12.5 12.5 15.0-8.0-8.1 28.9 25.0 7.0 20.8 154.4 Intellectual Property/Licensing $USm 40.0 40.0 72.9 52.8 61.7 61.1 80.0 125.7 122.8 122.3 Other $USm 14.6-48.6-14.4-31.3-30.2-30.9-34.0-45.7-61.1-60.5 EBITDA $USm 718.7 605.3 720.2 725.7 883.6 904.4 1324.0 1445.9 1788.0 2016.1 EBITDA growth -0.8% 0.6% 0.2% 19.9% 22.7% 24.6% -0.2% 9.2% 23.7% 12.8% Ebitda margin % 36.5% 28.5% 31.0% 31.7% 35.6% 35.7% 32.3% 31.3% 35.7% 37.0% - Depreciation $USm 67.1 65.3 71.5 76.8 83.1 86.2 132.5 148.3 169.3 188.2 % of sales 3.4% 3.1% 3.1% 3.4% 3.3% 3.4% 3.2% 3.2% 3.4% 3.5% - Amortisation 15.5 22.0 14.8 14.9 14.8 16.3 37.5 29.7 31.1 32.5 EBIT $USm 636.1 517.9 633.9 634.0 785.7 802.0 1154.0 1267.9 1587.7 1795.3 EBIT growth -1.6% -4.4% -0.3% 22.4% 23.9% 26.5% -2.9% 9.9% 25.2% 13.1% Ebit margin % 32.3% 24.4% 27.3% 27.7% 31.7% 31.7% 28.2% 27.5% 31.7% 32.9% - Net Interest Expense $USm -10.9-2.1 0.0-2.3 7.3 6.4-13.0-2.3 13.7 13.3 Pretax Profit $USm 647.0 520.0 633.9 636.3 778.4 795.6 1167.0 1270.2 1574.0 1782.1 - Tax Expense $USm 146.8 102.2 129.6 116.5 151.5 154.9 249.0 246.1 306.4 346.8 effective tax rate % 22.7% 19.7% 20.4% 18.3% 19.5% 19.5% 21.3% 19.4% 19.5% 19.5% Net Profit $USm 500.2 417.8 504.3 519.8 626.9 640.8 918.0 1024.1 1267.7 1435.2 + Net ISI $USm 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 + Net Extraordinaries $USm 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 - Minority Interests $USm 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Reported Profit $USm 500.2 417.8 504.3 519.8 626.9 640.8 918.0 1024.1 1267.7 1435.2 Adjusted Profit $USm 500.2 417.8 504.3 519.8 626.9 640.8 918.0 1024.1 1267.7 1435.2 Gross Cashflow $USm 582.8 505.2 590.6 611.5 724.8 743.2 1088.0 1202.1 1468.0 1656.0 23.8% 13.2% EPS (adj ISI & g/w / diluted incl NIA) 91.4 77.8 96.1 100.6 124.3 129.0 169.2 196.7 253.3 294.7 EPS adj Growth % 14.2% -5.8% 5.1% 29.4% 29.4% 28.2% 4.0% 16.3% 28.8% 16.3% DPS 35.0 43.1 36.0 50.5 50.0 55.0 78.1 86.5 105.0 125.0 EV/Sales 13.1 12.2 11.2 11.4 10.6 10.5 6.3 5.7 5.2 4.8 EV/EBIT 40.7 50.2 41.1 41.3 33.6 33.0 22.5 20.6 16.5 14.5 EV/EBITDA 36.0 42.9 36.1 36.1 29.9 29.3 19.6 18.1 14.7 12.9 PE (adj abn & g/w fully diluted) x 31.3 36.8 29.8 28.4 23.0 22.2 33.8 29.1 22.6 19.4 PGCFPS x 53.7 60.8 50.9 48.3 39.8 38.2 28.5 24.8 19.5 16.8 Yield % 0.6% 0.8% 0.6% 0.9% 0.9% 1.0% 1.4% 1.5% 1.8% 2.2% Franking % 0.0% 4.4% 0.0% 0.0% 0.0% 0.0% 2.4 0.0 0.0 0.0 Ord Fully Paid (Weighted Avg) m 542.9 524.8 519.4 506.9 498.2 492.0 524.8 506.9 492.0 485.8 EFPOWA m 547.4 537.1 525.0 516.3 504.3 496.6 542.3 520.6 500.5 487.1 Cashflow Analysis 1H/11A 2H/11A 1H/12A 2H/12A 1H/13A 2H/13E 2011A 2012A 2013E 2014E EBITDA $USm 718.7 605.3 720.2 725.7 883.6 904.4 1324.0 1445.9 1788.0 2016.1 - Inc. in Working capital $USm 136.4-89.7 41.2-44.6 41.2 52.3 46.8-3.4 93.5 165.7 - Net Interest Paid $USm -12.2-4.2 3.2-4.4 4.4 7.3-16.4-1.2 11.7 14.3 - Tax Paid $USm 186.0 102.7 136.9 107.8 167.8 151.5 288.7 244.7 319.3 325.6 + Other $USm 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Net Cash in Op Activities $USm 408.4 596.6 538.8 667.0 670.2 693.4 1005.0 1205.8 1363.6 1510.6 - Capex $USm 83.5 127.5 153.0 170.4 231.9 150.0 211.0 323.4 381.9 401.0 - Acquisitions $USm 2.6-2.6-0.8 0.8 5.2 0.0 0.0 0.0 5.2 0.0 + Asset Sales $USm 0.1 0.2 0.4-0.3 0.0 0.0 0.3 0.1 0.0 0.0 + Other $USm 0.0 1.0 0.0 1.1 0.2 0.0 1.0 1.1 0.2 0.0 Net cash in investing $USm -86.0-123.6-151.8-170.4-236.9-150.0-209.6-322.2-386.9-401.0 - Dividends Paid (before DRP) $USm 247.5 188.4 231.0 193.3 247.1 249.1 435.9 424.3 496.2 562.1 + Equity Movements (inc. DRP) $USm -290.8-592.6-177.8-462.0-451.3-355.0-883.4-639.8-806.3-355.0 + Debt Movements $USm -16.9 47.9 870.2-1.4-170.0 0.0 31.0 868.8-170.0 300.0 + Other $USm -0.2-0.1 0.6 0.0 0.1 0.0-0.3 0.6 0.1 0.0 Net cash in financing $USm -555.4-733.2 462.0-656.7-868.3-604.1-1288.6-194.7-1472.4-617.1 Opening Cash balance $USm 853.0 571.9 515.2 1317.2 1171.4 756.7 853.0 515.2 1171.4 696.0 Net Cash movement $USm -233.0-260.2 849.0-160.1-435.0-60.7-493.2 688.9-495.7 492.5 + Net Exchange Rate Differences $USm -48.1 203.6-47.0 14.3 20.3 0.0 155.4-32.7 20.3 0.0 Cash Balance + Cash $USm 571.9 515.2 1317.2 1171.4 756.7 696.0 515.2 1171.4 696.0 1188.5 Performance Analysis Balance Sheet 2011A 2012A 2013E 2014E Cash 515.2 1171.4 696.0 1188.5 FY13 EBIT breakdown Behring 90% OHH 3% IPL 7% FY13 Revenue breakdown OHH 19% IPL 3% Behring 78% Receivables 869.0 783.8 866.1 941.2 Inventory 1564.8 1482.7 1638.3 1780.3 Current Assets 19.3 7.2 7.1 7.1 Fixed Assets 1297.5 1380.9 1625.7 1838.5 Intangibles 983.4 865.3 869.2 836.7 Other 192.1 208.9 223.4 223.4 Total Assets 5441.3 5900.2 5925.9 6815.7 total asset growth 16.0% 8.4% 0.4% 15.0% Creditors 530.4 536.3 592.5 643.9 Other Current Liabilities 236.7 242.0 235.2 235.2 Long Term Debt 204.3 1073.1 903.1 1203.1 Other Liabilities 30.6 74.9 249.2 269.5 Net Assets 4196.2 3804.3 3938.8 4457.0 Shareholders Funds 3916.6 3476.7 3548.4 4066.6 Minority Interests 0.0 0.0 0.0 0.0 Total Shareholder Funds 3916.6 3476.7 3548.4 4066.6 Ratios 2011A 2012A 2013E 2014E Working Capital 1821 1635 1820 1986 D/(D+E) (%) -1.8% 2.0% 5.7% 0.5% Return on Equity (%) 23.4% 29.5% 35.7% 35.3% Return on Assets (%) 21.2% 21.5% 26.8% 26.3% NTA (est) ($) $5.41 $5.02 $5.35 $6.63 Source: Company data, Macquarie Research, April 2013 11 April 2013 5
Important disclosures: Recommendation definitions Macquarie - Australia/New Zealand Outperform return >3% in excess of benchmark return Neutral return within 3% of benchmark return Underperform return >3% below benchmark return Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield Macquarie Asia/Europe Outperform expected return >+10% Neutral expected return from -10% to +10% Underperform expected return <-10% Macquarie First South - South Africa Outperform expected return >+10% Neutral expected return from -10% to +10% Underperform expected return <-10% Macquarie - Canada Outperform return >5% in excess of benchmark return Neutral return within 5% of benchmark return Underperform return >5% below benchmark return Macquarie - USA Outperform (Buy) return >5% in excess of Russell 3000 index return Neutral (Hold) return within 5% of Russell 3000 index return Underperform (Sell) return >5% below Russell 3000 index return Volatility index definition* This is calculated from the volatility of historical price movements. Very high highest risk Stock should be expected to move up or down 60 100% in a year investors should be aware this stock is highly speculative. High stock should be expected to move up or down at least 40 60% in a year investors should be aware this stock could be speculative. Medium stock should be expected to move up or down at least 30 40% in a year. Low medium stock should be expected to move up or down at least 25 30% in a year. Low stock should be expected to move up or down at least 15 25% in a year. * Applicable to Australian/NZ/Canada stocks only Recommendations 12 months Note: Quant recommendations may differ from Fundamental Analyst recommendations Financial definitions : Global plasma report All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests EPS = adjusted net profit / efpowa* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards). Recommendation proportions For quarter ending 31 March 2013 AU/NZ Asia RSA USA CA EUR Outperform 45.12% 53.24% 50.00% 40.70% 62.98% 43.30% (for US coverage by MCUSA, 10.55% of stocks followed are investment banking clients) Neutral 41.52% 28.01% 41.43% 55.01% 32.60% 34.10% (for US coverage by MCUSA, 9.05% of stocks followed are investment banking clients) Underperform 13.36% 18.74% 8.57% 4.29% 4.42% 22.60% (for US coverage by MCUSA, 0.00% of stocks followed are investment banking clients) Company Specific Disclosures: Macquarie Bank Limited makes a market in the securities in respect of Limited. Macquarie and its affiliates collectively and beneficially own or control 1% or more of any class of Limited's equity securities. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures. Analyst Certification: The views expressed in this research reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd (ABN 94 122 169 279, AFSL No. 318062) ( MGL ) and its related entities (the Macquarie Group ) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. General Disclosure: This research has been issued by Macquarie Securities (Australia) Limited (ABN 58 002 832 126, AFSL No. 238947) a Participant of the Australian Securities Exchange (ASX) and Chi-X Australia Pty Limited. This research is distributed in Australia by Macquarie Equities Limited (ABN 41 002 574 923, AFSL No. 237504) ("MEL"), a Participant of the ASX, and in New Zealand by Macquarie Equities New Zealand Limited ( MENZ ) an NZX Firm. Macquarie Private Wealth s services in New Zealand are provided by MENZ. Macquarie Bank Limited (ABN 46 008 583 542, AFSL No. 237502) ( MBL ) is a company incorporated in Australia and authorised under the Banking Act 1959 (Australia) to conduct banking business in Australia. None of MBL, MGL or MENZ is registered as a bank in New Zealand by the Reserve Bank of New Zealand under the Reserve Bank of New Zealand Act 1989. Any MGL subsidiary noted in this research, apart from MBL, is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Australia) and that subsidiary s obligations do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of that subsidiary, unless noted otherwise. This research is general advice and does not take account of your objectives, financial situation or needs. Before acting on this general advice, you should consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision. This research has been prepared for the use of the clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. This research is based on information obtained from sources believed to be reliable, but the Macquarie Group does not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. The Macquarie Group accepts no liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. The Macquarie Group produces a variety of research products, recommendations contained in one type of research product may differ from recommendations contained in other types of research. The Macquarie Group has established and implemented a conflicts policy at group level, which may be revised and updated from time to time, pursuant to regulatory requirements; which sets out how we must seek to identify and manage all material conflicts of interest. The Macquarie Group, its officers and employees may have conflicting roles in the financial products referred to in this research and, as such, may effect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case. The Macquarie Group s employees or officers may provide oral or written opinions to its clients which are contrary to the opinions expressed in this research. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures. 11 April 2013 6